RENB Profile
Renovaro Biosciences Inc. is an innovative biotechnology company currently in its pre-clinical stage, focusing on the research and development of groundbreaking pharmaceutical and biological products aimed at treating human immunodeficiency virus (HIV), hepatitis B virus (HBV), and various cancers. Based in Los Angeles, California, the company is dedicated to advancing its pipeline of therapies, which includes several promising treatments under development. Renovaro’s portfolio features RENB-HV-01, an autologous therapy designed to provide a curative treatment for HIV; RENB-HV-12, a therapeutic HIV vaccine aimed at enhancing the body's immune response to the virus; and RENB-HB-01, a gene therapy approach intended to achieve a cure for HBV.
The company's cancer-focused initiatives are equally ambitious. Renovaro is developing RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine targeting pancreatic cancer, and RENB-DC-12-XX, which is designed for use against other solid tumors. These dendritic cell-based vaccines are designed to stimulate the immune system to recognize and attack cancer cells more effectively. Additionally, RENB-HV-21 represents an advanced approach to HIV treatment by employing allogeneic natural killer (NK) cells and gamma delta T-cells to combat the virus, reflecting the company’s commitment to leveraging cutting-edge immunotherapy technologies.
Renovaro Biosciences Inc. maintains strategic partnerships with notable research institutions, including the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. These collaborations enhance its research capabilities and provide valuable resources and expertise in advancing its therapeutic programs. The company’s strategic focus on integrating advanced immunotherapy and gene therapy reflects its goal of addressing unmet medical needs and providing transformative treatment options for HIV, HBV, and cancer.
Formerly known as Enochian Biosciences, Inc., the company rebranded to Renovaro Biosciences Inc. in August 2023 to better align with its evolving mission and expanded research focus. This rebranding marks a significant milestone in its ongoing efforts to push the boundaries of biotechnology and contribute to the advancement of medical science.
|
